About Nutra Pharma Corp CialisNow.com .Nutra Pharma Corp. Is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for treatment of neurological disorders, autoimmune and infectious diseases. Nutra Pharma Corp. Through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with drug development. ,, ReceptoPharm developing these technologies for the production of drugs for HIV and Multiple Sclerosis . The subsidiary, Designer Diagnostics, is developed in the research and development of diagnostic test kits to be used for the rapid identification of infectious diseases such as Paratuberculosis and Mycobacterium avium-intracellulare is committed. Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.
Nutra Pharma Subsidiary, ReceptoPharm, files patent application for novel treatment of arthritis with RPI-78 – Nutra Pharma Corp. Is a biotechnology company developing therapies for Adrenomyeloneuropathy , HIV and Multiple Sclerosis ), today announced that its wholly-owned drug discovery subsidiary , ReceptoPharm , has with the with the U.S. Patent and Trademark Office for the use of RPI-78 as a new method for treating arthritis in humans. RPI 78 ReceptoPharm leading drug candidates for the treatment of examined. Examined. – ‘In previous studies, we and others have found that peptides like RPI-78 were in the treatment of pain effectively with minimal side effects, almost no toxicity, and duration of effect is considerably greater than that of morphine, ‘explained Dr. Paul Reid, CEO of ReceptoPharm. ‘With our recent research , we have now confirmed that these proteins also have anti-inflammatory properties as well as what they can, an effective therapy for the treatment of arthritis or black box.
Since ‘the Obama administration willing to be laws, regulations or conflicts increase costs appears remove unnecessarily ‘to examine it should, a November 2008 Change in political policy, using the care on drug for off-label extension of to treat cancer patients, to for ‘likely ‘drift cost of , a New York Times editorial. The new policy has increased the number of reference sources and compendia of, instructed on Medicare is to determine which about blankets off-label using. The editorial staff that editors, many experts say the ‘effectiveness ‘new policy is that ‘virtually guarantee ‘that for most of the for most uses off-label. Although ‘[t] may have be in order’by the Matte Been ‘relevant and provides impartial, ‘they ‘few little clinical proof and are written by experts with a financial relations with the pharmaceuticals industry, ‘according to the editorial.
Subjects in this study visited women 50 to older, the non – adherent for mammography or Pap tests screening guidelines will had. Researchers developed an educational intervention , which has been administered by laymen health personnel. Following follow-up, researchers found that the screening end was higher than for women in the treatment group as a in the control group both to mammograms and Pap smear screening of. The study authors concluded, ‘We study provided further evidence showing that the lay health personnel model of may be increase cervical cancer cervical cancer among low-income Hispanic women. To low income effectiveness of the Cultivando La Salud: One Breast and Cervical Cancer screening of doctoral programs for low-income Hispanic women ‘.